TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04552899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRM-151 (Zinpentraxin Alfa)
Description: A 10 mg/kg IV infusion of PRM-151 based on the participants weight will be administered on Days 1, 3 and 5 followed by infusions Q4W to Week 48.
Study: NCT05449665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 1 - Control
Description: Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 - High Fibre
Description: High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 3 - Low Fibre
Description: Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
Study: NCT04552899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching PRM-151 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
Study: NCT05303701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 Placebo
Description: 0.9% normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GV1001 Placebo
Description: 0.9% normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 1.12mg
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GV1001 1.12mg
Description: Lyophilized peptide from hTERT
Study: NCT04673773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Massive Open Online Course
Description: Same as intervention
Study: NCT06041204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet
Description: Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
Study: NCT05094024

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Central kitchen-prepared version of MDCF-2
Description: Kitchen-prepared MDCF-2 containing chickpea flour, peanut flour, soybean flour, green banana pulp, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be freshly prepared in central kitchens on a daily basis and provided to participants on the same day. Every child in this arm will be offered 25g of the MDCF-2 formulation twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MDCF-2 shelf-stable foil pouch prototype with green banana powder
Description: This shelf-stable foil pouch prototype of MDCF-2 contains chickpea flour, peanut flour, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix, prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 21.77g of the formulation twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MDCF-2 shelf-stable foil pouch prototype with sweet potato
Description: This shelf-stable MDCF prototype contains chickpea flour, peanut flour, soybean flour, sweet potato, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 23.34g of the MDCF formulation twice daily.
Study: NCT06376968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioLogic Fusion
Description: Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioLogic Fusion
Description: Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.
Study: NCT05094024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freshly reconstituted MDCF-2 ingredients
Description: This version of MDCF-2 is comprised of its individually packaged ingredients. Separate premeasured sachets of chickpea flour, peanut paste, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix will be combined and reconstituted prior to each feeding session. Every child in this arm will be offered 21.72g of the formulation twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF) arm
Description: Locally-produced ready-to-use supplementary food (RUSF) is used as part of a nutritional program to treat moderate acute malnutrition in children over 6 months-of-age. RUSF is eaten directly from the package with no dilution, mixing or cooking. RUSF contains rice, lentil, powdered low-fat milk, soybean flour, sugar, and micronutrient mix. Every child in this arm will be offered 25g of the formulation twice daily.
Study: NCT05423834

Intervention type: DRUG
Intervention: Tenofovir alafenamide
Description: Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.

Intervention type: DRUG
Intervention: Entecavir
Description: Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
Study: NCT06003361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital CBT
Description: An app-based intervention based on principles from cognitive behavioral therapy for depression.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: Participants will wait for 5 weeks prior to receiving the intervention
Study: NCT05003674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused stimulation strategy
Description: Investigational focused stimulation strategy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACE stimulation strategy
Description: Standard of care stimulation strategy
Study: NCT04772898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The hippotherapy involves occupational therapy while being on a horse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hippotherapy
Description: The hippotherapy involves occupational therapy while being on a horse.
Study: NCT06277544

Intervention type: PROCEDURE
Intervention: lateral ankle ligament repair or reconstruction
Description: repair or reconstruction procedure for lateral ankle ligament

Intervention type: PROCEDURE
Intervention: lateral ankle ligament repair or reconstruction
Description: repair or reconstruction procedure for lateral ankle ligament
Study: NCT04919707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Header Session
Description: Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Header Session
Description: Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Session
Description: Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Session
Description: Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
Study: NCT05158569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow breathing exercise group
Description: The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise group
Description: Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting.
Study: NCT05685121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Neuro
Description: The device is a wearable nerve stimulator.
Study: NCT04748653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component reintegration intervention
Description: The intervention incorporates health education, psychosocial counseling, physiotherapy and economic investment.
Study: NCT05379036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prescribing anapproved drug, examination
Description: * Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prescribing anapproved drug, examination
Description: * Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prescribing anapproved drug, examination
Description: * Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months.
Study: NCT05228067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal transcranial direct current stimulation
Description: anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cathodal transcranial direct current stimulation
Description: anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)
Study: NCT05497323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Cream
Description: The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.

Intervention type: DRUG
Group type: OTHER
Intervention: Adapalene 0,1% cream
Description: Adapalene 0,1 % cream were given to subjects to be applied every night in group 1 and group 3, and intermittently every two nights in group 2.
Study: NCT05650502

Intervention type: DRUG
Intervention: saisonal malaria chimoprevention
Description: Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection

Intervention type: DRUG
Intervention: saisonal malaria chimoprevention
Description: Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
Study: NCT05115643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immobilization
Description: Immobilization of left arm using a brace and sling.
Study: NCT06429644

Intervention type: PROCEDURE
Intervention: Breast-conserving surgery
Description: Breast-conserving surgery, also known as breast-conserving therapy or lumpectomy, is a surgical procedure used to treat breast cancer while preserving as much of the breast tissue as possible. During this procedure, the surgeon removes the cancerous tumor along with a surrounding margin of normal tissue. The goal is to remove the cancerous cells while maintaining the appearance and function of the breast as much as possible.
Study: NCT05324917

Intervention type: DRUG
Intervention: Rituximab
Description: Chemotherapy for children with lymphoma: rituximab (375mg/m2 BSA) was added intravenously from COPADM1 regimen. once every 3 weeks to 4 weeks, combined with corresponding chemotherapy, a total of 4 times.

Intervention type: DRUG
Intervention: Rituximab (once a week)
Description: Rituximab (375mg/m2 BSA) was administered intravenously for lymphoproliferative diseases and EB virus-associated B lymphoproliferative diseases after hematopoietic stem cell transplantation. Once a week, a total of 4 times.~ITP and AIHA patients received rituximab (100mg/m2 BSA) intravenously once a week, a total of 4 times.
Study: NCT05630196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06174285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention with Psychedelic Virtual Reality
Description: A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic Intervention with Non-Psychedelic Virtual Reality
Description: A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
Study: NCT05027854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMS or tES
Description: Transcranial magnetic or electric stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham TMS or tES
Description: Sham transcranial magnetic or electric stimulation
Study: NCT05330689

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection dose (<5 billion platelets)
Description: PRP injection with a dose of platelets that is less than 5 billion platelets

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection dose (between 5 and <10 billion platelets)
Description: PRP injection with a dose of platelets that is between 5 and \<10 billion platelets

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection dose (between 10 and <20 billion platelets)
Description: PRP injection with a dose of platelets that is between 10 and \<20 billion platelets

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection dose (20 billion or greater platelets)
Description: PRP injection with a dose of platelets that is 20 billion platelets or greater

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection control
Description: Saline control
Study: NCT04747327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mandate public
Description: mandate by airlines, bars, restaurants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: employer mandate
Description: your employer requires vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive reward
Description: $1,000 tax credit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: penalty
Description: $1000 tax penalty

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive lottery small
Description: 100,000 smaller monetary amount

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive lottery medium
Description: 200,000 mid monetary amount

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive lottery large
Description: 1 million dollar lottery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash small
Description: smaller guaranteed cash amount

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash medium
Description: mid sized quarenteed cash amount

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash large
Description: large quarenteed cash amount

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invitation for exercise financial incentive study
Description: financial incentives earned when increasing exercise behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invitation for exercise social incentive study
Description: social incentives earned when increasing exercise behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invitation for sleep social incentive study
Description: social incentives earned when increasing sleep

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invitation for sleep financial incentive
Description: Financial incentives earned when increasing sleep